749 related articles for article (PubMed ID: 29382663)
1. Long Noncoding RNA lncSHGL Recruits hnRNPA1 to Suppress Hepatic Gluconeogenesis and Lipogenesis.
Wang J; Yang W; Chen Z; Chen J; Meng Y; Feng B; Sun L; Dou L; Li J; Cui Q; Yang J
Diabetes; 2018 Apr; 67(4):581-593. PubMed ID: 29382663
[TBL] [Abstract][Full Text] [Related]
2. Hepatic Activation of the FAM3C-HSF1-CaM Pathway Attenuates Hyperglycemia of Obese Diabetic Mice.
Chen Z; Ding L; Yang W; Wang J; Chen L; Chang Y; Geng B; Cui Q; Guan Y; Yang J
Diabetes; 2017 May; 66(5):1185-1197. PubMed ID: 28246289
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis.
Zhang M; Chi X; Qu N; Wang C
Biochem Biophys Res Commun; 2018 Apr; 499(1):66-70. PubMed ID: 29555473
[TBL] [Abstract][Full Text] [Related]
4. NFE2 Induces miR-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing the Hepatic FAM3A-ATP-Akt Pathway.
Yang W; Wang J; Chen Z; Chen J; Meng Y; Chen L; Chang Y; Geng B; Sun L; Dou L; Li J; Guan Y; Cui Q; Yang J
Diabetes; 2017 Jul; 66(7):1819-1832. PubMed ID: 28411267
[TBL] [Abstract][Full Text] [Related]
5. Dapper1 attenuates hepatic gluconeogenesis and lipogenesis by activating PI3K/Akt signaling.
Kuang JR; Zhang ZH; Leng WL; Lei XT; Liang ZW
Mol Cell Endocrinol; 2017 May; 447():106-115. PubMed ID: 28237722
[TBL] [Abstract][Full Text] [Related]
6. FAM3A activates PI3K p110α/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis.
Wang C; Chi Y; Li J; Miao Y; Li S; Su W; Jia S; Chen Z; Du S; Zhang X; Zhou Y; Wu W; Zhu M; Wang Z; Yang H; Xu G; Wang S; Yang J; Guan Y
Hepatology; 2014 May; 59(5):1779-90. PubMed ID: 24806753
[TBL] [Abstract][Full Text] [Related]
7. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c.
Hagiwara A; Cornu M; Cybulski N; Polak P; Betz C; Trapani F; Terracciano L; Heim MH; Rüegg MA; Hall MN
Cell Metab; 2012 May; 15(5):725-38. PubMed ID: 22521878
[TBL] [Abstract][Full Text] [Related]
8. Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance.
Sajan MP; Lee MC; Foufelle F; Sajan J; Cleland C; Farese RV
Cell Signal; 2018 Mar; 43():62-70. PubMed ID: 29269047
[TBL] [Abstract][Full Text] [Related]
9. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis.
Li S; Brown MS; Goldstein JL
Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3441-6. PubMed ID: 20133650
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of long non-coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non-alcoholic fatty liver disease.
Li T; Huang X; Yue Z; Meng L; Hu Y
Cell Biochem Funct; 2020 Oct; 38(7):839-846. PubMed ID: 32212193
[TBL] [Abstract][Full Text] [Related]
11. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes.
Liu TY; Shi CX; Gao R; Sun HJ; Xiong XQ; Ding L; Chen Q; Li YH; Wang JJ; Kang YM; Zhu GQ
Clin Sci (Lond); 2015 Nov; 129(10):839-50. PubMed ID: 26201094
[TBL] [Abstract][Full Text] [Related]
12. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte-secreted FAM3D ameliorates hepatic steatosis by activating FPR1-hnRNP U-GR-SCAD pathway to enhance lipid oxidation.
Hu Y; Li J; Li X; Wang D; Xiang R; Liu W; Hou S; Zhao Q; Yu X; Xu M; Zhao D; Li T; Chi Y; Yang J
Metabolism; 2023 Sep; 146():155661. PubMed ID: 37454871
[TBL] [Abstract][Full Text] [Related]
14. The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver.
Hörbelt T; Knebel B; Fahlbusch P; Barbosa D; de Wiza DH; Van de Velde F; Van Nieuwenhove Y; Lapauw B; Thoresen GH; Al-Hasani H; Müller-Wieland D; Ouwens DM; Kotzka J
Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2671-2684. PubMed ID: 31336149
[TBL] [Abstract][Full Text] [Related]
15. Tangshen formula attenuates hepatic steatosis by inhibiting hepatic lipogenesis and augmenting fatty acid oxidation in db/db mice.
Kong Q; Zhang H; Zhao T; Zhang W; Yan M; Dong X; Li P
Int J Mol Med; 2016 Dec; 38(6):1715-1726. PubMed ID: 27840945
[TBL] [Abstract][Full Text] [Related]
16. Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5'-UTR in a cellular model of hepatic steatosis.
Siculella L; Tocci R; Rochira A; Testini M; Gnoni A; Damiano F
Biochim Biophys Acta; 2016 May; 1861(5):471-81. PubMed ID: 26869449
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.
Wu H; Zhang T; Pan F; Steer CJ; Li Z; Chen X; Song G
J Hepatol; 2017 Apr; 66(4):816-824. PubMed ID: 28025059
[TBL] [Abstract][Full Text] [Related]
18. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
[TBL] [Abstract][Full Text] [Related]
19. Hepatic mTOR-AKT2-Insig2 signaling pathway contributes to the improvement of hepatic steatosis after Roux-en-Y Gastric Bypass in mice.
Pan Q; Qin T; Gao Y; Li S; Li D; Peng M; Zhai H; Xu G
Biochim Biophys Acta Mol Basis Dis; 2019 Mar; 1865(3):525-534. PubMed ID: 30562559
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
